[ News ] [ Our People ]
[ Management Team ] [ Board of Directors ]
Mohr, Ph.D., R.Psych., ICD.D
Chairman & Chief Executive Officer
Founder of MedGenesis Therapeutix Inc.
Dr. Mohr is the Chairman and CEO of MedGenesis Therapeutix Inc. which he
founded in 2006. Dr. Mohr, a Professor of Medicine and Psychology at the
University of Ottawa until 1997 has over 30 years of experience in experimental
therapeutics of CNS disorders. He is credited with over 150 publications, book
chapters and abstracts and has edited the Handbook of Clinical Trials: The
neurobehavioral approach. Dr. Mohr has chaired and/or served on several
regulatory advisory panels for the approval of new products for the treatment of
neurodegenerative disease and is the former Chairman and Chief Executive Officer
of CroMedica Global Inc. (which merged with PRA International in 2002 to form
one of the world's leading contract research organizations) and is the current
or past Chairman of several biotechnology companies. His most recent executive
position was with PRA International as Chief Scientific Officer. He also served
until recently as Chair of the Board of Governors of the University of Victoria.
Over the course of his career, Dr. Mohr has overseen and/or participated in more
than a dozen clinical development programs resulting in a number of approved drugs.
Matthias Luz, M.D.
Chief Medical Officer
Dr. Luz earned his MD from Heidelberg University, Germany, where he also
trained as an anesthesiologist and intensive care physician. After becoming
board-certified, Dr. Luz joined the biopharmaceutical industry where he spent
the past 25 years, acquiring extensive experience in preclinical and clinical
drug development including regulatory affairs. Before joining MedGenesis in 2006
to lead all of the company's development efforts, Dr. Luz was the Vice President
and Head, Global Product Development Services for PRA International. In this
capacity, Dr. Luz led an accomplished team of senior physician-scientists and
drug development experts involved in the design and implementation of high
quality development programs from pre-IND to Phase 3 and submission. During a
previous tenure at Behringwerke/Hoechst Marion Roussel/Aventis, Dr. Luz led the
team that brought Refludan®, the first therapeutic for
heparin-induced thrombocytopenia, to market worldwide. Dr. Luz also held other
senior positions at Knoll/Abbott and Cardion.
Lara Longpre, M.Sc., MBA
Chief Operating Officer
Ms. Longpre re-joined MedGenesis in October 2014 as Chief Operating Officer.
She brings to MedGenesis more than 24 years of experience developing innovative
and complex therapies, most recently as Chief Operating Officer at Jennerex
Biotherapeutics. As COO, she was responsible for program management for the lead
product, alliance management across 3 international collaboration partners,
clinical operations for over 11 clinical trials, technical operations,
regulatory affairs, and quality assurance. Prior to Jennerex, Ms. Longpre was
Senior Vice-President, Clinical & Corporate Affairs at MedGenesis where she was
responsible for business operations including the intellectual property
portfolio, corporate files, and clinical development plans and budgets. Ms.
Longpre continued to serve as a consultant to MedGenesis during her tenure at
Jennerex. Ms. Longpre previously held several senior positions with PRA
International/CroMedica including operations, regulatory affairs, and proposals
& contracts. She holds a BA in Biology from Cornell University, an MSc from
Harvard Medical School and an MBA from Queen's University.